Related Experiment Video
Updated: Oct 8, 2026

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Pneumocystis jirovecii pneumonia in liver transplant recipients: a systematic review
I D Kostakis1, G C Sotiropoulos1, G Kouraklis1
1Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Background:
Pneumocystis jirovecii is a fungus that causes pneumonia in immunocompromised patients, such as liver transplant recipients.
Methods:
We searched the Medline database in September 2013 for articles referring to infections from P. jirovecii in liver transplant recipients, using the terms "liver transplantation" and "pneumocystis." Our search yielded 60 articles, 35 of which were used for our review.
Results:
P. jirovecii pneumonia (PJP) has an incidence of 1%-11% in liver transplant recipients without prophylaxis and mortality rates of 7%-88%. Most cases occur within the first 7 months after transplantation. When prophylactic treatment with oral trimethoprim-sulfamethoxazole is used, its incidence is only 0%-3%. The duration of its use varies from 3 months to 1 year after the liver transplantation.
Conclusions:
PJP has relatively high incidence and high mortality rates in liver transplant recipients without prophylactic treatment, which diminishes or even eliminates its occurrence. Therefore, oral trimethoprim-sulfamethoxazole should be used as prophylaxis for 1 year after the liver transplantation in this population.
Insights
Prophylactic trimethoprim-sulfamethoxazole significantly reduces the incidence and mortality of Pneumocystis jirovecii pneumonia (PJP) in liver transplant recipients. Extended use for one year post-transplant is recommended to prevent this opportunistic infection.
Area of Science:
- Infectious Diseases
- Transplant Surgery
- Mycology
Background:
- Pneumocystis jirovecii causes pneumonia in immunocompromised individuals.
- Liver transplant recipients are particularly susceptible to P. jirovecii infections.
Purpose of the Study:
- To review the incidence and outcomes of P. jirovecii pneumonia (PJP) in liver transplant recipients.
- To evaluate the effectiveness of prophylactic treatment for PJP in this patient population.
Main Methods:
- A systematic literature search was conducted using Medline.
- Keywords included "liver transplantation" and "pneumocystis."
- 35 relevant articles were selected for review from 60 initial results.
Main Results:
- PJP incidence in liver transplant recipients without prophylaxis ranges from 1% to 11%, with mortality rates between 7% and 88%.
- Most PJP cases occur within 7 months post-transplantation.
- Prophylaxis with oral trimethoprim-sulfamethoxazole reduces PJP incidence to 0%-3%.
Conclusions:
- PJP poses a significant risk of high incidence and mortality in liver transplant recipients without prophylaxis.
- Oral trimethoprim-sulfamethoxazole prophylaxis is highly effective in preventing PJP.
- Prophylaxis should be administered for one year following liver transplantation.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Pneumonia I: Introduction

